Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

• DOI: 10.1038/sj.bjc.6604410
• Publication Date: 2008-05-27T14:22:01Z
• Authors: G Ferrandina; M Petrillo; A Carbone; G Zannoni; E Martinelli; M Prisco; S Pignata; E Breda; A Savarese; G Scambia
• Keywords: Ovarian Neoplasms; Middle Aged; Prognosis; Immunohistochemistry; 3. Good health; DNA-Binding Proteins; 03 medical and health sciences; DNA Topoisomerases, Type II; 0302 clinical medicine; Ovarian cancer; Prognosis; Topoisomerase-IIα; Antigens, Neoplasm; Drug Resistance, Neoplasm; Clinical Study; Humans; Female; Aged

To our knowledge, very few data about the role of Topoisomerase IIα (TOPO-IIα), an enzyme involved in critical steps tumour cell proliferation and chemoresistance are currently available ovarian cancer patients. The aim this study was to investigate prognostic value TOPO-IIα expression a large, single institution series 96 primary untreated advanced patients admitted Gynecologic Oncology Unit, Catholic University Campobasso Rome. Immunohistochemistry carried out by using MoAb anti-human antibody (clone Ki-S1). immunoreaction observed 70 cases (72.9%), percentages positively stained cells ranged between 1 83% (median=10%). There no association with clinico-pathological parameters. During follow up period, progression death disease were 76 (79.2%) 45 (46.9%) cases. A statistically significant direct immunostained relative risk (χ2=6.6, P-value=0.0101). In multivariate analysis, only platinum resistance, stage high levels retained independent negative for OS. unfavourable maintained subgroup resistant recurrent patients, be evaluated as continuous variable (χ2=5.1, P-value=0.024), or means defined cutoff point. Our suggests that assessment could helpful identify poor prognosis platinum-resistant potentially candidates investigational agents.